at the end of a two-week single-blind placebo baseline , 43 patients with a diagnosis of panic disorder with agoraphobia without significant dysphoria-depression and with moderate to severe panic and phobic symptoms were assigned to , and 32 of them completed , a placebo-controlled ( n = 7 ) dose-response study with three weight-adjusted imipramine hydrochloride dosages : 0.5 mg/kg/d ( n = 10 ) , 1.5 mg/kg/d ( n = 9 ) , and 3 mg/kg/d ( n = 6 ) .
C0030319
panic disorder
C0589978
imipramine hydrochloride